Pharmaceutical Executive August 8, 2024
The two companies will combine assets to develop a device that make automatic adjustments.
Abbott has partnered with Medtronic to develop an integrated continuous glucose monitoring system.1 The project will incorporate Abbott’s FreeStyle Libre technology and Medtronic’s automated insulin delivery (AID) system and smart insulin pens.
According to Abbott, the combination of technologies should allow the device to make automatic adjustments to insulin based on glucose levels.
In a press release, Abbott’s executive vice president of its diabetes care business Jared Watkin said, “This partnership pairs two global leaders in glucose sensing technology and insulin delivery. Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic’s insulin delivery systems...
Today's Sponsors
Today's Sponsor